Myriad Genetics (MYGN) Misses Q2 EPS by 8c, Guidance Misses

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.23, $0.08 worse than the analyst estimate of $0.31. Revenue for the quarter came in at $195.1 million versus the consensus estimate of $209.81 million.

GUIDANCE:

Myriad Genetics sees Q3 2020 EPS of $0.02, versus the consensus of $0.30. Myriad Genetics sees Q3 2020 revenue of $172 million, versus the consensus of $201.22 million.

Myriad Genetics sees FY2020 EPS of $0.45, versus the consensus of $1.06. Myriad Genetics sees FY2020 revenue of $735 million, versus the consensus of $807.31 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• Presidents Capital Management Reiterates Strong Buy (1) Rating on Sea Ltd. (SE)